The Role of Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase-2 Inhibitors on Experimental Colitis

dc.contributor.authorPaiotti, Ana Paula Ribeiro [UNIFESP]
dc.contributor.authorMarchi, Patricia [UNIFESP]
dc.contributor.authorMiszputen, Sender Jankiel [UNIFESP]
dc.contributor.authorOshima, Celina Tizuko Fujiyama [UNIFESP]
dc.contributor.authorFranco, Marcello Fabiano de [UNIFESP]
dc.contributor.authorRibeiro, Daniel Araki [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2018-06-15T17:38:31Z
dc.date.available2018-06-15T17:38:31Z
dc.date.issued2012-05-01
dc.description.abstractThe nonsteroidal anti-inflammatory drugs (NSAIDs) have been widely used in the management of pain and inflammation. Unfortunately, they are associated with dose-dependent gastrointestinal (GI) adverse events ranging from dyspepsia to symptomatic and complicated ulcers. The mechanism of NSAID action is attributed to the cyclooxygenase (COX) inhibition. New anti-inflammatory drugs have been synthesized, such as selective COX-2 inhibitors, however, these drugs may present side effects, such as modification of the epithelial barrier. Inflammatory bowel disease (IBD) is a common chronic gastrointestinal disorder characterized by alternating periods of remission and active intestinal inflammation. A possible association between the use of NSAIDs and the relapse of IBD has been repeatedly suggested. For this reason, many studies are conducted with the use of COX-2 in experimental models. The objective of this review is to describe the role of NSAIDs and COX-2 inhibitors in different experimental models of colitis. We reviewed controlled trials, original articles, case reports and reviews. The role of selective inhibition of COX-2 in the inflammatory process and the course of experimental and human colitis is controversially discussed. In conclusion, the relative role of COX-2 selective inhibitors on human and experimental colitis remains to be explored. Thus, the use of COX-2 inhibitors in IBD should be considered with caution.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Biosci, BR-11060001 Santos, SP, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Dept Pathol, BR-11060001 Santos, SP, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Div Gastroenterol, BR-11060001 Santos, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Biosci, BR-11060001 Santos, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Pathol, BR-11060001 Santos, SP, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Gastroenterol, BR-11060001 Santos, SP, Brazil
dc.description.sourceWeb of Science
dc.format.extent381-393
dc.identifierhttp://iv.iiarjournals.org/content/26/3/381.full
dc.identifier.citationIn Vivo. Athens: Int Inst Anticancer Research, v. 26, n. 3, p. 381-393, 2012.
dc.identifier.issn0258-851X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/43916
dc.identifier.wosWOS:000303351100006
dc.language.isoeng
dc.publisherInt Inst Anticancer Research
dc.relation.ispartofIn Vivo
dc.rightsAcesso aberto
dc.subjectNSAIDsen
dc.subjectCOX-2 inhibitorsen
dc.subjectIBDen
dc.subjectexperimental colitisen
dc.subjectcyclooxygenaseen
dc.subjectreviewen
dc.titleThe Role of Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase-2 Inhibitors on Experimental Colitisen
dc.typeResenha
Arquivos